{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,26]],"date-time":"2026-05-26T23:02:22Z","timestamp":1779836542489,"version":"3.53.1"},"reference-count":28,"publisher":"SAABRON PRESS","issue":"2","license":[{"start":{"date-parts":[[2026,5,26]],"date-time":"2026-05-26T00:00:00Z","timestamp":1779753600000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"abstract":"<jats:sec id=\"background\">\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>\n                      VEXAS (vacuoles, E1 enzyme, X-linked, autoinflammatory, somatic) syndrome is caused by somatic\n                      <jats:italic>UBA1<\/jats:italic>\n                      mutations and frequently complicated by myelodysplastic syndrome (MDS). Conventional immunosuppressive and anti-inflammatory therapies are often ineffective, and allogeneic hematopoietic stem cell transplantation (allo-HSCT) is currently the only curative treatment, although its optimal timing and donor selection remain uncertain.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec id=\"case-presentation\">\n                    <jats:title>Case Presentation<\/jats:title>\n                    <jats:p>\n                      A 67-year-old man with VEXAS syndrome and MDS harboring\n                      <jats:italic>UBA1<\/jats:italic>\n                      (p.M41T) and\n                      <jats:italic>EZH2<\/jats:italic>\n                      mutations, refractory to azacitidine and corticosteroids, successfully underwent allo-HSCT from a one-antigen\u2013mismatched related donor. Post-transplant chronic graft-versus-host disease was well controlled with ruxolitinib.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec id=\"methods-and-results\">\n                    <jats:title>Methods and Results<\/jats:title>\n                    <jats:p>\n                      We reviewed eight studies comprising 45 allo-HSCT recipients with VEXAS syndrome. The median age at transplantation was 59 years, and patients had received a median of five prior systemic therapies. MDS was present in 53.3% of cases, while 42.2% underwent transplantation for VEXAS without overt hematologic malignancy. The most frequent\n                      <jats:italic>UBA1<\/jats:italic>\n                      variant was p.Met41Val (37.8%). At last follow-up, 84.4% of patients were alive, with resolution of inflammatory manifestations in most cases.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec id=\"conclusion\">\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>Allo-HSCT represents a curative option for refractory VEXAS syndrome. Comprehensive genetic profiling may aid in identifying candidates for early transplantation. If early transplantation is required, human leukocyte antigen-mismatched donors may be selected.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.46989\/001c.161719","type":"journal-article","created":{"date-parts":[[2026,5,26]],"date-time":"2026-05-26T22:03:24Z","timestamp":1779833004000},"source":"Crossref","is-referenced-by-count":0,"title":["Allogeneic hematopoietic stem cell transplantation for VEXAS syndrome: A review and a case report"],"prefix":"10.46989","volume":"8","author":[{"given":"Kentaro","family":"Nagae","sequence":"first","affiliation":[{"name":"Department of Hematology\/Oncology, Kurashiki Central Hospital, Kurashiki, Okayama, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3195-2322","authenticated-orcid":true,"given":"Hiroyuki","family":"Muranushi","sequence":"additional","affiliation":[{"name":"Department of Hematology\/Oncology, Kurashiki Central Hospital, Kurashiki, Okayama, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yasuhito","family":"Nannya","sequence":"additional","affiliation":[{"name":"Division of Hematopoietic Disease Control, The Institute of Medical Science, The University of Tokyo, Tokyo, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Takeshi","family":"Maeda","sequence":"additional","affiliation":[{"name":"Department of Hematology\/Oncology, Kurashiki Central Hospital, Kurashiki, Okayama, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"26435","published-online":{"date-parts":[[2026,5,26]]},"reference":[{"issue":"2 Suppl","key":"ref1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jtct.2023.12.397","article-title":"Pilot prospective study of reduced intensity conditioning allogeneic hematopoietic stem cell transplantation in patients with Vexas syndrome","volume":"30","author":"A. A. Mangaonkar","year":"2024","journal-title":"Transplant Cell Ther"},{"issue":"5","key":"ref2","doi-asserted-by":"publisher","first-page":"777","DOI":"10.1111\/bjh.18488","article-title":"Allogeneic haematopoietic stem cell transplantation for VEXAS syndrome: UK experience","volume":"199","author":"A. Al-Hakim","year":"2022","journal-title":"Br J Haematol"},{"issue":"27","key":"ref3","doi-asserted-by":"publisher","first-page":"2628","DOI":"10.1056\/NEJMoa2026834","article-title":"Somatic mutations in UBA1 and severe adult-onset autoinflammatory disease","volume":"383","author":"D. B. Beck","year":"2020","journal-title":"N Engl J Med"},{"issue":"3","key":"ref4","doi-asserted-by":"publisher","first-page":"e12","DOI":"10.1111\/bjh.18424","article-title":"Case report: up-front allogeneic stem cell transplantation in a patient with the VEXAS syndrome","volume":"199","author":"N. van Leeuwen-Kerkhoff","year":"2022","journal-title":"Br J Haematol"},{"issue":"2","key":"ref5","doi-asserted-by":"publisher","first-page":"315","DOI":"10.1038\/s41409-021-01544-y","article-title":"Allogeneic stem cell transplantation as a curative therapeutic approach for VEXAS syndrome: a case report","volume":"57","author":"M. Loschi","year":"2022","journal-title":"Bone Marrow Transplant"},{"issue":"6","key":"ref6","doi-asserted-by":"publisher","first-page":"1444","DOI":"10.1182\/bloodadvances.2023012478","article-title":"Allogeneic hematopoietic cell transplantation for VEXAS syndrome: results of a multicenter study of the EBMT","volume":"8","author":"C. Gurnari","year":"2024","journal-title":"Blood Adv"},{"issue":"7","key":"ref7","doi-asserted-by":"publisher","first-page":"1285","DOI":"10.1002\/art.42471","article-title":"Novel somatic UBA1 variant in a patient with VEXAS syndrome","volume":"75","author":"B. Stiburkova","year":"2023","journal-title":"Arthritis Rheumatol"},{"issue":"2","key":"ref8","doi-asserted-by":"publisher","first-page":"254","DOI":"10.1002\/ajh.27169","article-title":"Diagnostic capabilities, clinical features, and longitudinal UBA1 clonal dynamics of a nationwide VEXAS cohort","volume":"99","author":"C. Gurnari","year":"2024","journal-title":"Am J Hematol"},{"key":"ref9","doi-asserted-by":"publisher","first-page":"1383730","DOI":"10.3389\/fonc.2024.1383730","article-title":"Successful treatment with fludarabine and cyclophosphamide in a VEXAS syndrome patient with associated myelodysplastic syndrome: a case report and systematic review","volume":"14","author":"P. Bellman","year":"2024","journal-title":"Front Oncol"},{"issue":"10","key":"ref10","doi-asserted-by":"publisher","first-page":"1423","DOI":"10.1038\/s41409-024-02375-3","article-title":"Assessing the efficacy of allogeneic hematopoietic cell transplantation in VEXAS syndrome: results of a systematic review and meta-analysis","volume":"59","author":"R. Mohty","year":"2024","journal-title":"Bone Marrow Transplant"},{"issue":"6","key":"ref11","doi-asserted-by":"publisher","first-page":"919","DOI":"10.1007\/s12185-023-03532-y","article-title":"Successful azacitidine therapy for myelodysplastic syndrome associated with VEXAS syndrome","volume":"117","author":"A. Kataoka","year":"2023","journal-title":"Int J Hematol"},{"issue":"3","key":"ref12","doi-asserted-by":"publisher","first-page":"244","DOI":"10.1182\/blood.2022018774","article-title":"Spectrum of clonal hematopoiesis in VEXAS syndrome","volume":"142","author":"F. Gutierrez-Rodrigues","year":"2023","journal-title":"Blood"},{"key":"ref13","doi-asserted-by":"publisher","first-page":"4177","DOI":"10.1038\/ncomms5177","article-title":"Ezh2 loss promotes development of myelodysplastic syndrome but attenuates its predisposition to leukaemic transformation","volume":"5","author":"G. Sashida","year":"2014","journal-title":"Nat Commun"},{"key":"ref14","doi-asserted-by":"publisher","first-page":"106999","DOI":"10.1016\/j.leukres.2022.106999","article-title":"Clinical characteristics and outcomes of EZH2-mutant myelodysplastic syndrome: a large single institution analysis of 1774 patients","volume":"124","author":"S. Ball","year":"2023","journal-title":"Leuk Res"},{"issue":"25","key":"ref15","doi-asserted-by":"publisher","first-page":"2338","DOI":"10.1056\/NEJMoa2215943","article-title":"Post-transplantation cyclophosphamide-based graft-versus-host disease prophylaxis","volume":"388","author":"J. Bola\u00f1os-Meade","year":"2023","journal-title":"N Engl J Med"},{"issue":"3","key":"ref16","doi-asserted-by":"publisher","first-page":"344","DOI":"10.1038\/s41409-023-02162-6","article-title":"Posttransplant cyclophosphamide in unrelated and related peripheral blood stem cell transplantation from HLA-matched and 1 allele mismatched donor","volume":"59","author":"J. Sugita","year":"2024","journal-title":"Bone Marrow Transplant"},{"issue":"23","key":"ref17","doi-asserted-by":"publisher","first-page":"2566","DOI":"10.1200\/JCO-24-02477","article-title":"Ruxolitinib in patients with corticosteroid-refractory or corticosteroid-dependent chronic graft-versus-host disease: 3-year final analysis of the Phase III REACH3 Study","volume":"43","author":"R. Zeiser","year":"2025","journal-title":"J Clin Oncol"},{"issue":"19","key":"ref18","doi-asserted-by":"publisher","first-page":"1800","DOI":"10.1056\/NEJMoa1917635","article-title":"Ruxolitinib for glucocorticoid-refractory acute graft-versus-host disease","volume":"382","author":"R. Zeiser","year":"2020","journal-title":"N Engl J Med"},{"issue":"8","key":"ref19","doi-asserted-by":"publisher","first-page":"927","DOI":"10.1182\/blood.2022016642","article-title":"Ruxolitinib is more effective than other JAK inhibitors to treat VEXAS syndrome: a retrospective multicenter study","volume":"140","author":"M. Heiblig","year":"2022","journal-title":"Blood"},{"issue":"5","key":"ref20","doi-asserted-by":"publisher","first-page":"2617","DOI":"10.1007\/s00277-025-06382-2","article-title":"Emerging treatment approaches for VEXAS syndrome: a systematic review and meta-analysis","volume":"104","author":"B. Kilic","year":"2025","journal-title":"Ann Hematol"},{"issue":"3","key":"ref21","doi-asserted-by":"publisher","first-page":"564","DOI":"10.1111\/bjd.20805","article-title":"Further characterization of clinical and laboratory features in VEXAS syndrome: large-scale analysis of a multicentre case series of 116 French patients","volume":"186","author":"S. Georgin-Lavialle","year":"2022","journal-title":"Br J Dermatol"},{"issue":"13","key":"ref22","doi-asserted-by":"publisher","first-page":"1496","DOI":"10.1182\/blood.2022016985","article-title":"Translation of cytoplasmic UBA1 contributes to VEXAS syndrome pathogenesis","volume":"140","author":"M. A. Ferrada","year":"2022","journal-title":"Blood"},{"issue":"6","key":"ref23","doi-asserted-by":"publisher","first-page":"298","DOI":"10.1097\/RHU.0000000000001905","article-title":"VEXAS syndrome\u2014a review of pathophysiology, presentation, and prognosis","volume":"29","author":"M. J. Koster","year":"2023","journal-title":"J Clin Rheumatol"},{"issue":"11","key":"ref24","doi-asserted-by":"publisher","first-page":"3518","DOI":"10.1093\/rheumatology\/kead240","article-title":"How to treat VEXAS syndrome: a systematic review on effectiveness and safety of current treatment strategies","volume":"62","author":"Z. Boyadzhieva","year":"2023","journal-title":"Rheumatology (Oxford)"},{"issue":"11","key":"ref25","doi-asserted-by":"publisher","first-page":"4427","DOI":"10.1007\/s00277-024-05942-2","article-title":"Role of allogeneic hematopoietic cell transplantation in VEXAS syndrome","volume":"103","author":"A. L. Dias","year":"2024","journal-title":"Ann Hematol"},{"issue":"7","key":"ref26","doi-asserted-by":"publisher","first-page":"4428","DOI":"10.1093\/rheumatology\/keaf196","article-title":"New X for VEXAS: haploidentical allogeneic haematopoietic cell transplantation in VEXAS syndrome","volume":"64","author":"S. Hug","year":"2025","journal-title":"Rheumatology (Oxford)"},{"issue":"14","key":"ref27","doi-asserted-by":"publisher","first-page":"7095","DOI":"10.1111\/jcmm.16591","article-title":"Next-generation sequencing in two cases of de novo acute basophilic leukaemia","volume":"25","author":"T. Shimizu","year":"2021","journal-title":"J Cell Mol Med"},{"issue":"3","key":"ref28","doi-asserted-by":"publisher","first-page":"998","DOI":"10.1182\/bloodadvances.2021004749","article-title":"Successful allogeneic hematopoietic stem cell transplantation in patients with VEXAS syndrome: a 2-center experience","volume":"6","author":"A. Diarra","year":"2022","journal-title":"Blood Adv"}],"container-title":["Clinical Hematology International"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/chi.scholasticahq.com\/article\/161719-allogeneic-hematopoietic-stem-cell-transplantation-for-vexas-syndrome-a-review-and-a-case-report","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,5,26]],"date-time":"2026-05-26T22:03:25Z","timestamp":1779833005000},"score":1,"resource":{"primary":{"URL":"https:\/\/chi.scholasticahq.com\/article\/161719-allogeneic-hematopoietic-stem-cell-transplantation-for-vexas-syndrome-a-review-and-a-case-report"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,5,26]]},"references-count":28,"journal-issue":{"issue":"2","published-online":{"date-parts":[[2026]]}},"URL":"https:\/\/doi.org\/10.46989\/001c.161719","relation":{},"ISSN":["2590-0048"],"issn-type":[{"value":"2590-0048","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,5,26]]}}}